Ligand for peroxisome proliferator-activated receptor γ (Troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo

Cancer Research

Volumn 58, Issue 15, 1998, Pages 3344-3352

  Kubota, Tetsuya ^a   Koshizuka, Kozo ^a   Williamson, Elizabeth A ^a   Asou, Hiroya ^a   Said, Jonathan W ^a   Holden, Stuart ^a   Miyoshi, Isao ^b   Koeffler, H Phillip ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b KOCHI MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

6 [1 (5,6,7,8 TETRAHYDRO 3,5,5,8,8 PENTAMETHYL 2 NAPHTHYL)CYCLOPROPYL]NICOTINIC ACID; 7 (3,5 DI TERT BUTYLPHENYL) 3 METHYL 2,4,6 OCTATRIENOIC ACID; ALITRETINOIN; CIGLITAZONE; INDOMETACIN; PEROXISOME PROLIFERATOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PROSTAGLANDIN D2 DERIVATIVE; RETINOIC ACID; RETINOIC ACID RECEPTOR; RETINOID X RECEPTOR; ROSIGLITAZONE; SR 11345; TROGLITAZONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL DIFFERENTIATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; HUMAN; HUMAN CELL; MALE; MOUSE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROSTATE CANCER;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL CYCLE; CELL DIFFERENTIATION; CHROMANS; DRUG SYNERGISM; HUMANS; LIGANDS; MALE; MICE; MICE, NUDE; PROSTATIC NEOPLASMS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; THIAZOLES; THIAZOLIDINEDIONES; TRANSCRIPTION FACTORS; TRETINOIN; TUMOR CELLS, CULTURED;

EID: 0032145363     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Parker, S. L., Tong, T., Bolden, S., and Wingo, P. A. Cancer Statistics. CA Cancer J. Clin., 46: 5-27, 1996.
2. Garnick, M. B. Prostate cancer: screening, diagnosis, and management. Ann. Intern. Med., 118: 804-818, 1993.
3. Warrell, R. P., Jr., Frankel, S. R., Miller, W. H., Jr., Scheinberg, D. A., Itri, L. M., Hittelman, W. N., Vyas, R., Andreeff, M., Tafuri, A., Jakubowski, A., Gabrilove, J., Gordon, M. S., and Dmitrovsky, E. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N. Engl. J. Med., 324: 1385-1393, 1991.
4. Castaigne, S., Chomienne, C., Daniel, M. T., Ballerini, P., Berger, R., Fernaux, P., and Degos, L. All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood, 76: 1704-1709, 1990.
5. Tontonoz, P., Hu, E., and Spiegelman, B. M. Stimulation of adipogenesis in fibroblasts by PPARγ2 a lipid-activated transcription factor. Cell, 79: 1147-1156, 1994.
6. Chawla, A., Schwarz, E. J., Dimaculangan, D. D., and Lazar, M. A. Peroxisome proliferator-activated receptor (PPAR) γ: adipose-predominant expression and induction early in adipocyte differentiation. Endocrinology, 135: 798-800, 1994.
7. Hu, E., Tontonoz, P., and Spiegelman, B. M. Transdifferentiation of myoblasts by the adipogenic transcription factors PPARγ and C/EBPα. Proc. Natl. Acad. Sci. USA, 92: 9856-9860, 1995.
8. Kliewer, S. A., Umesono, K., Noonan, D. J., Heyman, R. A., and Evans, R. M. Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature (Lond.), 358: 771-774, 1992.
9. Kliewer, S. A., Forman, B. M., Blumberg, B., Ong, E. S., Borgmeyer, U., Mangelsdorf, D. J., Umesono, K., and Evans, R. M. Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc. Natl. Acad. Sci. USA, 91: 7355-7359, 1994.
10. Dreyer, C., Krey, G., Keller, H., Givel, F., Helftenbein, G., and Wahli, W. Control of the peroxisomal β-oxidation pathway by a novel family of nuclear hormone receptors. Cell, 68: 879-887, 1992.
11. Negrel, R., Gaillard, D., and Ailhaud, G. Prostacyclin as a potent effector of adipose-cell differentiation. Biochem. J., 257: 399-405, 1989.
12. Lepak, N. M., and Serrero, G. Inhibition of adipose differentiation by 9α,11β-prostaglandin F2α. Prostaglandins, 46: 511-517, 1993.
13. Yu, K., Bayona, W., Kallen, C. B., Harding, H. P., Ravera, C. P., McMahon, G., Brown, M., and Lazar, M. A. Defferential activation of peroxisome proliferator-activated receptors by eicosanoids. J. Biol. Chem., 270: 23975-23983, 1995.
14. 2 is a ligand for the adipocyte determination factor PPARγ. Cell, 83: 803-812, 1995.
15. 2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation. Cell, 83: 813-819, 1995.
16. Lin, F., and Lane, M. D. CCAAT/enhancer binding protein α is sufficient to initiate the 3T3-L1 adipocyte differentiation program. Proc. Natl. Acad. Sci. USA, 91: 8757-8761, 1994.
17. Fujiwara, T., Yoshioka, S., Yoshioka, T., Ushiyama, I., and Horikoshi, H. Characterization of new oral antidiabetic agent CS-045. Studies in KK and ob/ob mice and Zucker fatty rats. Diabetes, 37: 1549-1558, 1988.
18. Ciaraldi, T. P., Gilmore, A., Olefsky, J. M., Goldberg, M., and Heidenreich, K. A. In vitro studies on the action of CS-045, a new antidiabetic agent. Metabolism, 39: 1056-1062, 1990.
19. Nolan, J. J., Ludvik, B., Beerdsen, P., Joyce, M., and Olefsky, J. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N. Engl. J. Med., 331: 1188-1193, 1994.
20. Lehmann, J. M., Moore, L. B., Smith-Oliver, T. A., Wilkison, W. O., Willson, T. M., and Kliewer, S. A. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ). J. Biol. Chem., 270: 12953-12956, 1995.
21. Mukherjee, R., Davies, P. J. A., Crombie, D. L., Bischoff, E. D., Cesario, R. M., Jow, L., Hamann, L. G., Boehm, M. F., Mondon, C. E., Nadzan, A. M., Paterniti, J. R., Jr., and Heyman, R. A. Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists. Nature (Lond.), 386: 407-410, 1997.
22. Tontonoz, P., Singer, S., Forman, B. M., Sarraf, P., Fletcher, J. A., Fletcher, C. D. M., Brun, R. P., Mueller, E., Altiok, S., Oppenheim, H., Evans, R. M., and Spiegelman, B. M. Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor γ and the retinoid X receptor. Proc. Natl. Acad. Sci. USA, 94: 237-241, 1997.
23. Mueller, E., Sarraf, P., Tontonoz, P., Evans, R. M., Martin, K. J., Zhang, M., Fletcher, C., Singer, S., and Spiegelman, B. M. Terminal differentiation of human breast cancer though PPARγ. Mol. Cell., 1: 465-470, 1998.
24. deVos, S., Dawson, M. I., Holden, S., Le, T., Wang, A., Cho, S. K., Chen, D., and Koeffler, H. P. Effects of retinoid X receptor-selective ligands on proliferation of prostate cancer cells. Prostate, 32: 115-121, 1997.
25. Pollard, M., Luckert, P. H., and Sporn, M. B. Prevention of primary prostate cancer in Lobund-Wistar rats by N-(4-hydroxyphenyl)retinamide. Cancer Res., 51: 3610-3611, 1991.
26. Slawin, K., Kadmon, D., Park, S. H., Scardino, P. T., Anzano, M., Sporn, M. B., and Thompson, T. C. Dietary fenretinide, a synthetic retinoid, decreases the tumor incidence and the tumor mass of ras+myc-induced carcinomas in the mouse prostate reconstitution model system. Cancer Res., 53: 4461-4465, 1993.
27. Munker, R., Norman, A., and Koeffler, H. P. Vitamin D compounds. Effect on clonal proliferation and differentiation of human myeloid cells. J. Clin. Invest., 78: 424-430, 1986.
28. kip1 and E-cadherin. J. Mol. Endocrinol., 19: 15-27, 1997.
29. 3 analogues: a novel class of potent inhibitors of proliferation and inducers of differentiation of human breast cancer cell lines. Cancer Res., 55: 2822-2830, 1995.
30. 3 receptors and actions in human prostate cancer cell lines. Endocrinology, 132: 1952-1960, 1993.
31. Katz, A. E., Seaman, E., Olsson, C. A., O'Toole, K. M., Raffo, A. J., McMahon, D., Cama, C., Benson, M. C., Perlman, H., and Buttyan, R. Molecular staging of prostate cancer with the use of an enhanced reverse transcriptase-PCR assay. Urology, 43: 765-775, 1994.
32. Otto, T., Rembrink, K., Goepel, M., Meyer-Schwickerath, M., and Rübben, H. E-cadherin: a marker for differentiation and invasiveness in prostate carcinoma. Urol. Res., 21: 359-362, 1993.
33. Green, H., and Kehinde, O. Sublines of mouse 3T3 cells that accumulate lipid. Cell, 1: 113-116, 1974.
34. Abbadia, Z., Vericel, E., Mathevet, P., Bertin, N., Panaye, G., and Frappart, L. Fatty acid composition and CD36 expression in breast adipose tissue of premenopausal and postmenopausal women. Anticancer Res., 17: 1217-1222, 1997.
35. Said, J. W., Chien, K., Takeuchi, S., Tasaka, T., Asou, H., Cho, S. K., de Vos, S., Cesarman, E., Knowles, D. M., and Koeffler, H. P. Kaposi's sarcoma-associated herpesvirus (KSHV or HHV8) in primary effusion lymphoma: ultrastructural demonstration of herpesvirus in lymphoma cells. Blood, 87: 4937-4943, 1996.
36. Elbrecht, A., Chen, Y., Cullinan, C. A., Hayes, N., Leibowits, M. D., Moller, D. E., and Berger, J. Molecular cloning, expression and characterization of human peroxisome proliferator activated receptors γ1 and γ2. Biochem. Biophys. Res. Commun., 224: 431-437, 1996.
37. Ricote, M., Li, A. C., Willson, T. M., Kelly, C. J., and Glass, C. K. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature (Lond.), 391: 79-82, 1998.
38. Issemann. I., and Green, S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature (Lond.), 347: 645-650, 1990.
39. Spiegelman, B. M. PPARγ in monocytes: less pain, any gain? Cell, 93: 153-155, 1998.